Quoted from http://www.reuters.com/article/2011/12/07/us-sanofi-lantus-idUSTRE7B60NA20111207
Sanofi rebuffs renewed Lantus cancer worries
LONDON | Wed Dec 7, 2011 6:27am EST
LONDON (Reuters) - A Swedish study has rekindled concerns about a possible link between Sanofi's top-selling insulin drug Lantus and cancer, but the French drugmaker said on Wednesday the observational research was seriously flawed.
It said separate data would be presented on December 8 showing no increased risk of cancer among patients taking its $4.7 billion-a-year product.
The Swedish research, which looked at the medical records of 23,000 people in the southwest of the country in an attempt to find common links to cancer, found an apparent doubling of cancer risk in those taking Sanofi's long-acting insulin.
[Article continues at original source]